Tekla Capital Management LLC Sarepta Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 179,437 shares of SRPT stock, worth $28.3 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

179,437

Previous 285,653 37.18%

Holding current value

$28.3 Million

Previous $39.4 Million 47.81%

% of portfolio

0.81%

Previous 1.51%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$106.4 - $157.19 $11.3 Million - $16.7 Million	-106,216 Reduced 37.18%	179,437 $20.5 Million
Q1 2023 May 10, 2023	BUY	$117.53 - $155.99 $17 Million - $22.6 Million	144,694 Added 102.65%	285,653 $39.4 Million
Q4 2022 Feb 10, 2023	SELL	$100.86 - $132.13 $2.52 Million - $3.3 Million	-25,000 Reduced 15.06%	140,959 $18.3 Million
Q3 2022 Nov 01, 2022	SELL	$75.71 - $119.24 $3.5 Million - $5.51 Million	-46,206 Reduced 21.78%	165,959 $18.3 Million
Q2 2022 Jul 29, 2022	SELL	$62.69 - $88.44 $973,701 - $1.37 Million	-15,532 Reduced 6.82%	212,165 $15.9 Million

Q1 2022 May 13, 2022	SELL	$63.15 - $90.42 $5.57 Million - $7.98 Million	-88,200 Reduced 27.92%	227,697 $17.8 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $8.55 Million - $11 Million	-110,617 Reduced 25.94%	315,897 $28.4 Million
Q3 2021 Nov 12, 2021	BUY	$65.97 - $92.48 $15.4 Million - $21.6 Million	233,290 Added 120.74%	426,514 $39.4 Million
Q2 2021 Aug 13, 2021	BUY	$69.38 - $86.75 $4.46 Million - $5.57 Million	64,237 Added 49.8%	193,224 $15 Million
Q1 2021 May 14, 2021	SELL	$72.25 - $168.95 $5.6 Million - $13.1 Million	-77,500 Reduced 37.53%	128,987 $9.61 Million
Q3 2020 Nov 13, 2020	BUY	$127.12 - $172.34 $8.44 Million - $11.4 Million	66,358 Added 47.35%	206,487 $29 Million
Q1 2020 May 14, 2020	SELL	$82.38 - $131.64 $3.42 Million - $5.46 Million	-41,494 Reduced 22.85%	140,129 $13.7 Million
Q4 2019 Feb 13, 2020	BUY	$76.53 - $135.58 $3.16 Million - $5.61 Million	41,344 Added 29.47%	181,623 $23.4 Million
Q3 2019 Nov 13, 2019	SELL	$72.81 - $156.91 $551,026 - $1.19 Million	-7,568 Reduced 5.12%	140,279 $10.6 Million
Q1 2019 May 14, 2019	SELL	$106.67 - $151.68 $4.69 Million - $6.67 Million	-43,990 Reduced 22.93%	147,847 $17.6 Million
Q4 2018 Feb 13, 2019	SELL	$97.32 - $148.76 $3.05 Million - $4.66 Million	-31,345 Reduced 14.04%	191,837 $20.9 Million
Q3 2018 Nov 13, 2018	SELL	$115.31 - $161.51 $1.3 Million - $1.83 Million	-11,307 Reduced 4.82%	223,182 $36 Million
Q2 2018 Aug 13, 2018	SELL	$71.74 - $153.69 $10.3 Million - $22.1 Million	-144,027 Reduced 38.05%	234,489 $31 Million
Q1 2018 May 14, 2018	BUY	$54.02 - $82.27 $2.38 Million - $3.63 Million	44,116 Added 13.19%	378,516 $28 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $9.63 Million - $11.5 Million	-202,200 Reduced 37.68%	334,400 $18.6 Million
Q3 2017 Nov 13, 2017	BUY	$35.73 - $47.15 $893,249 - $1.18 Million	25,000 Added 4.89%	536,600 $24.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	511,600	511,600 $17.2 Million

Others Institutions Holding SRPT

# of Institutions

470

Shares Held

79.3M

Call Options Held

4.23M

Put Options Held

1.21M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $13.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Sarepta Therapeutics, Inc. Transaction History